132 related articles for article (PubMed ID: 24446026)
1. A phase II study of cediranib as palliative treatment in patients with symptomatic malignant ascites or pleural effusion.
Mulder SF; Boers-Sonderen MJ; van der Heijden HF; Vissers KC; Punt CJ; van Herpen CM
Target Oncol; 2014 Dec; 9(4):331-8. PubMed ID: 24446026
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Batchelor TT; Duda DG; di Tomaso E; Ancukiewicz M; Plotkin SR; Gerstner E; Eichler AF; Drappatz J; Hochberg FH; Benner T; Louis DN; Cohen KS; Chea H; Exarhopoulos A; Loeffler JS; Moses MA; Ivy P; Sorensen AG; Wen PY; Jain RK
J Clin Oncol; 2010 Jun; 28(17):2817-23. PubMed ID: 20458050
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites.
Colombo N; Mangili G; Mammoliti S; Kalling M; Tholander B; Sternas L; Buzenet G; Chamberlain D
Gynecol Oncol; 2012 Apr; 125(1):42-7. PubMed ID: 22112608
[TBL] [Abstract][Full Text] [Related]
4. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
Garland LL; Chansky K; Wozniak AJ; Tsao AS; Gadgeel SM; Verschraegen CF; Dasilva MA; Redman M; Gandara DR
J Thorac Oncol; 2011 Nov; 6(11):1938-45. PubMed ID: 21964533
[TBL] [Abstract][Full Text] [Related]
5. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study.
Lee JM; Cimino-Mathews A; Peer CJ; Zimmer A; Lipkowitz S; Annunziata CM; Cao L; Harrell MI; Swisher EM; Houston N; Botesteanu DA; Taube JM; Thompson E; Ogurtsova A; Xu H; Nguyen J; Ho TW; Figg WD; Kohn EC
J Clin Oncol; 2017 Jul; 35(19):2193-2202. PubMed ID: 28471727
[TBL] [Abstract][Full Text] [Related]
6. Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.
Campbell NP; Kunnavakkam R; Leighl N; Vincent MD; Gandara DR; Koczywas M; Gitlitz BJ; Agamah E; Thomas SP; Stadler WM; Vokes EE; Kindler HL
Lung Cancer; 2012 Oct; 78(1):76-80. PubMed ID: 22831987
[TBL] [Abstract][Full Text] [Related]
7. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer.
Sjoquist KM; Espinoza D; Mileshkin L; Ananda S; Shannon C; Yip S; Goh J; Bowtell D; Harrison M; Friedlander ML
Gynecol Oncol; 2021 May; 161(2):374-381. PubMed ID: 33637349
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer.
Li J; Al-Huniti N; Henningsson A; Tang W; Masson E
Br J Clin Pharmacol; 2017 Aug; 83(8):1723-1733. PubMed ID: 28213941
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: a phase II study.
Zhu AX; Ancukiewicz M; Supko JG; Sahani DV; Blaszkowsky LS; Meyerhardt JA; Abrams TA; McCleary NJ; Bhargava P; Muzikansky A; Sheehan S; Regan E; Vasudev E; Knowles M; Fuchs CS; Ryan DP; Jain RK; Duda DG
Clin Cancer Res; 2013 Mar; 19(6):1557-66. PubMed ID: 23362324
[TBL] [Abstract][Full Text] [Related]
10. Microdialysis measurement of intratumoral temozolomide concentration after cediranib, a pan-VEGF receptor tyrosine kinase inhibitor, in a U87 glioma model.
Grossman R; Tyler B; Rudek MA; Kim E; Zadnik P; Khan U; Blakeley JO; Pathak AP; Brem H
Cancer Chemother Pharmacol; 2013 Jul; 72(1):93-100. PubMed ID: 23649683
[TBL] [Abstract][Full Text] [Related]
11. Cediranib in combination with fulvestrant in hormone-sensitive metastatic breast cancer: a randomized Phase II study.
Hyams DM; Chan A; de Oliveira C; Snyder R; Vinholes J; Audeh MW; Alencar VM; Lombard J; Mookerjee B; Xu J; Brown K; Klein P
Invest New Drugs; 2013 Oct; 31(5):1345-54. PubMed ID: 23801303
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
van Cruijsen H; Voest EE; Punt CJ; Hoekman K; Witteveen PO; Meijerink MR; Puchalski TA; Robertson J; Saunders O; Jürgensmeier JM; van Herpen CM; Giaccone G
Eur J Cancer; 2010 Mar; 46(5):901-11. PubMed ID: 20061136
[TBL] [Abstract][Full Text] [Related]
13. Rapid development of hypertension and proteinuria with cediranib, an oral vascular endothelial growth factor receptor inhibitor.
Robinson ES; Matulonis UA; Ivy P; Berlin ST; Tyburski K; Penson RT; Humphreys BD
Clin J Am Soc Nephrol; 2010 Mar; 5(3):477-83. PubMed ID: 20056761
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of cediranib, an oral VEGF inhibitor, in previously untreated patients with metastatic or recurrent malignant melanoma.
McWhirter E; Quirt I; Gajewski T; Pond G; Wang L; Hui J; Oza A
Invest New Drugs; 2016 Apr; 34(2):231-5. PubMed ID: 26841902
[TBL] [Abstract][Full Text] [Related]
15. Population exposure-safety analysis of cediranib for Phase I and II studies in patients with cancer.
Al-Huniti N; Petersson K; Tang W; Masson E; Li J
Br J Clin Pharmacol; 2018 Apr; 84(4):726-737. PubMed ID: 29274100
[TBL] [Abstract][Full Text] [Related]
16. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer.
Dahut WL; Madan RA; Karakunnel JJ; Adelberg D; Gulley JL; Turkbey IB; Chau CH; Spencer SD; Mulquin M; Wright J; Parnes HL; Steinberg SM; Choyke PL; Figg WD
BJU Int; 2013 Jun; 111(8):1269-80. PubMed ID: 23419134
[TBL] [Abstract][Full Text] [Related]
17. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
18. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.
Heiss MM; Murawa P; Koralewski P; Kutarska E; Kolesnik OO; Ivanchenko VV; Dudnichenko AS; Aleknaviciene B; Razbadauskas A; Gore M; Ganea-Motan E; Ciuleanu T; Wimberger P; Schmittel A; Schmalfeldt B; Burges A; Bokemeyer C; Lindhofer H; Lahr A; Parsons SL
Int J Cancer; 2010 Nov; 127(9):2209-21. PubMed ID: 20473913
[TBL] [Abstract][Full Text] [Related]
19. Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29.
Laurie SA; Solomon BJ; Seymour L; Ellis PM; Goss GD; Shepherd FA; Boyer MJ; Arnold AM; Clingan P; Laberge F; Fenton D; Hirsh V; Zukin M; Stockler MR; Lee CW; Chen EX; Montenegro A; Ding K; Bradbury PA
Eur J Cancer; 2014 Mar; 50(4):706-12. PubMed ID: 24360368
[TBL] [Abstract][Full Text] [Related]
20. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Gotlieb WH; Amant F; Advani S; Goswami C; Hirte H; Provencher D; Somani N; Yamada SD; Tamby JF; Vergote I
Lancet Oncol; 2012 Feb; 13(2):154-62. PubMed ID: 22192729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
